Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R Benramdane
Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide
Haematologica
Hematology
PUK32 Lower Case Mix Adjusters Are Associated With Lower Erythropoiesis-Stimulating Agent (ESA) and Other Bundled Costs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Familial Clubfoot With or Without Associated Lower Limb Anomalies
Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression
Annals of Hematology
Medicine
Hematology
The Role of Ineffective Erythropoiesis in Non-Transfusion-Dependent Thalassemia
Blood Reviews
Oncology
Hematology
